In situ androgen production in human gastric carcinoma - Androgen synthesizing and metabolizing enzymes

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1935-1939

  Nakamura, Yasuhiro ^a   Shimada, Norihiro ^a   Suzuki, Takashi ^a   Imatani, Akira ^a   Sekine, Hitoshi ^a   Ohara, Syuichi ^a   Shimosegawa, Tooru ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric carcinoma; Immunohistochemistry; In situ androgen production

Indexed keywords

ANDROGEN RECEPTOR; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1 ENZYME; STEROID 5ALPHA REDUCTASE 2 ENZYME; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 5 ENZYME; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENDOSCOPIC MUCOSAL RESECTION; ENZYME ASSAY; ENZYME METABOLISM; FEMALE; HISTOPATHOLOGY; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CARCINOMA;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; STOMACH NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33745588840     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Everett SM and Axon AT: Early gastric cancer in Europe. Gut 41: 142-150, 1997.
2. Kim JP, Lee JH, Kim SJ, Yu HJ and Yang HK: Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1: 125-133, 1998.
3. Sipponen P and Correa P: Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 5: 213-219, 2002.
4. Tanaka K, Kiyohara Y, Kato I, Matsumoto T, Yamagata H, Kubo M, Tanizaki Y, Okubo K, Nakamura H, Iwamoto H, Nakayama K and Iida M: Incidence and prognosis of gastric cancer in a population-based cohort survey: the Hisayama study. Scand J Gastroenterol 39: 459-463, 2004.
5. Tokunaga A, Nishi K, Matsukura N, Tanaka N, Onda M, Shirota A, Asano G and Hayashi K: Estrogen and progesterone receptors in gastric cancer. Cancer 57: 1376-1379, 1986.
6. Wu CW, Chi CW, Chang TJ, Lui WY and P'eng FK: Sex hormone receptors in gastric cancer. Cancer 65: 1396-1400, 1990.
7. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JA and Hayashi S: Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 128: 319-324, 2002.
8. Saitoh Y, Sasano H, Naganuma H, Ohtani H, Sasano N, Ohuchi A and Matsuno S: De novo expression of aromatase in gastric carcinoma. Light and electron microscopic immunohistochemical and immunoblot study. Pathol Res Pract 188: 53-60, 1992.
9. Matsui M, Kojima O, Kawakami S, Uehara Y and Takahashi T: The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 22: 421-425, 1992.
10. Korenaga D, Orita H, Okuyama T, Kinoshita J, Maekawa S, Ikeda T and Sugimachi K: Sex hormone-receptor-negative tumors have a higher proliferative activity than sex hormone-receptor-positive tumors in human adenocarcinomas of the gastrointestinal tract. Surg Today 28: 1007-1014, 1998.
11. Takano N, Iizuka N, Hazama S, Yoshino S, Tangoku A and Oka M: Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett 176: 129-135, 2002.
12. Kominea A, Konstantinopoulos PA, Kapranos N, Vandoros G, Gkermpesi M, Andricopoulos P, Artelaris S, Savva S, Varakis I, Sotiropoulou-Bonikou G and Papavassiliou AG: Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol 130: 253-258, 2004.
13. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H: In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12: 101-107, 2005.
14. Russell DW and Wilson JD: Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 63: 25-61, 1994.
15. Dufort I, Rheault P, Huang XF, Soucy P and Luu-The V: Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140: 568-574, 1999.
16. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD and Russell DW: Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 90: 799-809, 1992.
17. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD and Russell DW: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92: 903-910, 1993.
18. Pelletier G, Luu-The V, Tetu B and Labrie F: Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 47: 731-738, 1999.
19. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, Soini Y and Vihko PT: 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64: 7604-7609, 2004.
20. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G and Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
21. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K and Nakanishi M: Cyclin E as a coactivator of the androgen receptor. J Cell Biol 150: 873-880, 2000.